Catalent and Triphase Accelerator Corporation have signed a license agreement under which Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP antibody-drug conjugate (ADC), which has been developed by Catalent’s subsidiary, Redwood Bioscience, using its SMARTag technology platform. Catalent will receive an upfront payment and has the potential to earn additional development and commercial milestone payments, plus a royalty on product sales. Triphase, which...